Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial
March 10, 2025 07:00 ET
|
Lungpacer Medical USA Inc.
Lungpacer Medical is excited to announce approval of an Investigational Device Exemption (IDE) from the U.S. FDA for the STARI clinical study.
Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical Ventilation
February 20, 2025 07:00 ET
|
Lungpacer Medical USA Inc.
Lungpacer Medical Announces Positive Results from STIMULUS Trial: Diaphragm Neurostimulation Improves Hemodynamic Performance During Mechanical Ventilation
Lungpacer Medical Announces Premarket Approval for AeroPace® System
December 05, 2024 09:00 ET
|
Lungpacer Medical USA Inc.
EXTON, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free patients from mechanical ventilation...
Lungpacer Medical Announces PMA Submission for AeroPace® System
September 04, 2024 09:00 ET
|
Lungpacer Medical USA Inc.
Lungpacer Medical today announced that its AeroPace System is under Food and Drug Administration (FDA) review in a premarket approval (PMA) application.
Lungpacer Medical Accelerates Pivotal Clinical Study with AeroPaceā¢ System
February 14, 2022 11:49 ET
|
Lungpacer Medical USA Inc.
EXTON, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Lungpacer Medical, a leading medical device innovation company, today announced the introduction of the AeroPaceā¢ System, a next generation product,...